Beam Therapeutics Inc. (BEAM) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Beam Therapeutics Inc. (BEAM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

23.21

-2.33 (-9.12%)

At close: Jan 14, 2025, 3:59 PM

23.21

0.00%

After-hours Jan 14, 2025, 07:01 PM EST

undefined% (undefined)

Bid	22
Market Cap	1.92B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.58
PE Ratio (ttm)	-14.69
Forward PE	n/a
Analyst	Buy

Ask	24
Volume	2,033,777
Avg. Volume (20D)	1,196,014
Open	25.50
Previous Close	25.54
Day's Range	22.80 - 25.61
52-Week Range	20.84 - 49.50
Beta	undefined

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 6, 2020

Employees 472

Stock Exchange NASDAQ

Ticker Symbol BEAM

Website https://www.beamtx.com

Analyst Forecast

According to 10 analyst ratings, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $48, which is an increase of 106.81% from the latest price.

Buy 60.00%

Hold 40.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Beam Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $15.12M, reflecting a -95.22% YoY shrinking and earnings per share of -1.28, making a -173.99% decrease YoY.

Why Price Moved

1 month ago · Source

+5.49%

Beam Therapeutics shares are trading higher. The c... Unlock content with Pro Subscription

2 months ago · Source

+11.24%

Beam Therapeutics shares are trading higher after Leerrink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $27 to $39.

News

2 days ago · zacks.com

Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?

Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

5 days ago · schaeffersresearch.com

2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy

Beam Therapeutics (BEAM) Gene editing firm Beam Therapeutics is developing its own pipeline with base editing as its foundation technology, a technique that changes a single DNA or RNA base without cu...

3 weeks ago · zacks.com

5 Biotech Breakthrough Stocks to Watch in 2025

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen...

1 month ago · zacks.com

Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19.

1 month ago · zacks.com

Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024...

2 months ago · zacks.com

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development.

2 months ago · seekingalpha.com

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications Jo...

2 months ago · zacks.com

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago.